215 related articles for article (PubMed ID: 27183528)
21. Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to "Omics" Technologies.
Madonna R
Rev Esp Cardiol (Engl Ed); 2017 Jul; 70(7):576-582. PubMed ID: 28246019
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors.
Maurea N; Coppola C; Piscopo G; Galletta F; Riccio G; Esposito E; De Lorenzo C; De Laurentiis M; Spallarossa P; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e19-e26. PubMed ID: 27755239
[TBL] [Abstract][Full Text] [Related]
23. Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies.
Cadeddu C; Mercurio V; Spallarossa P; Nodari S; Triggiani M; Monte I; Piras R; Madonna R; Pagliaro P; Tocchetti CG; Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e64-e75. PubMed ID: 27755244
[TBL] [Abstract][Full Text] [Related]
24. Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Magdy T; Burmeister BT; Burridge PW
Pharmacol Ther; 2016 Dec; 168():113-125. PubMed ID: 27609196
[TBL] [Abstract][Full Text] [Related]
25. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
26. Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.
Mercuro G
J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1():S1-2. PubMed ID: 27183519
[No Abstract] [Full Text] [Related]
27. Cardiotoxicity associated with cancer therapy: pathophysiology and prevention strategies.
Adão R; de Keulenaer G; Leite-Moreira A; Brás-Silva C
Rev Port Cardiol; 2013 May; 32(5):395-409. PubMed ID: 23623503
[TBL] [Abstract][Full Text] [Related]
28. Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity.
Cadeddu Dessalvi C; Deidda M; Noto A; Madeddu C; Cugusi L; Santoro C; López-Fernández T; Galderisi M; Mercuro G
Antioxid Redox Signal; 2021 Mar; 34(7):572-588. PubMed ID: 32151144
[No Abstract] [Full Text] [Related]
29. The cardiotoxicity of anticancer agents.
Von Hoff DD; Rozencweig M; Piccart M
Semin Oncol; 1982 Mar; 9(1):23-33. PubMed ID: 7071608
[TBL] [Abstract][Full Text] [Related]
30. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
31. [Cardiotoxicity of cancer therapy].
Marek J; Linhart A; Rucklová Z; Haber J; Korínek J
Vnitr Lek; 2011 May; 57(5):472-84. PubMed ID: 21695928
[TBL] [Abstract][Full Text] [Related]
32. Metabolomic Profiles on Antiblastic Cardiotoxicity: New Perspectives for Early Diagnosis and Cardioprotection.
Fazzini L; Caggiari L; Deidda M; Onnis C; Saba L; Mercuro G; Cadeddu Dessalvi C
J Clin Med; 2022 Nov; 11(22):. PubMed ID: 36431222
[TBL] [Abstract][Full Text] [Related]
33. Cardio-oncology Related to Heart Failure: Pediatric Considerations for Cardiac Dysfunction.
Rose-Felker K; Border WL; Hong BJ; Chow EJ
Heart Fail Clin; 2017 Apr; 13(2):311-325. PubMed ID: 28279417
[TBL] [Abstract][Full Text] [Related]
34. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
35. An update on the risk prediction and prevention of anticancer therapy-induced cardiotoxicity.
Bhave M; Shah AN; Akhter N; Rosen ST
Curr Opin Oncol; 2014 Nov; 26(6):590-9. PubMed ID: 25233068
[TBL] [Abstract][Full Text] [Related]
36. Trastuzumab and target-therapy side effects: Is still valid to differentiate anthracycline Type I from Type II cardiomyopathies?
Riccio G; Coppola C; Piscopo G; Capasso I; Maurea C; Esposito E; De Lorenzo C; Maurea N
Hum Vaccin Immunother; 2016 May; 12(5):1124-31. PubMed ID: 26836985
[TBL] [Abstract][Full Text] [Related]
37. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
38. Management of Heart Failure in Cancer Patients and Cancer Survivors.
Finet JE
Heart Fail Clin; 2017 Apr; 13(2):253-288. PubMed ID: 28279414
[TBL] [Abstract][Full Text] [Related]
39. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
40. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
